

0570  
0530

# 8



OIPE

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/894,550

DATE: 06/04/2002

TIME: 13:25:51

Input Set : A:\083AUSSEQ LST.txt

Output Set: N:\CRF3\06042002\I894550.raw

ENTERED

3 <110> APPLICANT: Abbott Laboratories  
 4 Collinson, Albert  
 5 Ghayur, Tariq  
 6 Avgerinos, George  
 7 Dixon, Richard  
 8 Kaymakcalan, Zehra  
 10 <120> TITLE OF INVENTION: DUAL SPECIFICITY ANTIBODIES AND METHODS OF MAKING AND USING  
 12 <130> FILE REFERENCE: BBC-083A US  
 14 <140> CURRENT APPLICATION NUMBER: US 09/894,550  
 15 <141> CURRENT FILING DATE: 2001-06-28  
 17 <150> PRIOR APPLICATION NUMBER: US 60/215,379  
 18 <151> PRIOR FILING DATE: 2000-06-29  
 20 <160> NUMBER OF SEQ ID NOS: 4  
 22 <170> SOFTWARE: PatentIn version 3.1  
 24 <210> SEQ ID NO: 1  
 25 <211> LENGTH: 9  
 26 <212> TYPE: PRT  
 27 <213> ORGANISM: Artificial Sequence  
 29 <220> FEATURE:  
 30 <223> OTHER INFORMATION: dual specificity antigen  
 32 <400> SEQUENCE: 1  
 34 Asn Glu Ala Gln Asn Ile Thr Asp Phe  
 35 1 5  
 38 <210> SEQ ID NO: 2  
 39 <211> LENGTH: 18  
 40 <212> TYPE: PRT  
 41 <213> ORGANISM: Artificial Sequence  
 43 <220> FEATURE:  
 44 <223> OTHER INFORMATION: consensus sequence  
 46 <220> FEATURE:  
 47 <221> NAME/KEY: misc\_feature  
 48 <222> LOCATION: (18)..(18)  
 49 <223> OTHER INFORMATION: Xaa is Pro or Gly  
 52 <400> SEQUENCE: 2  
 54 Met Ala Phe Leu Arg Ala Asn Gln Asn Asn Gly Lys Ile Ser Val Ala  
 55 1 5 10 15  
 58 Leu Xaa  
 62 <210> SEQ ID NO: 3  
 63 <211> LENGTH: 16  
 64 <212> TYPE: PRT  
 65 <213> ORGANISM: Artificial Sequence  
 67 <220> FEATURE:  
 68 <223> OTHER INFORMATION: hybrid peptide

## RAW SEQUENCE LISTING

DATE: 06/04/2002

PATENT APPLICATION: US/09/894,550

TIME: 13:25:51

Input Set : A:\083AUSSEQ LST.txt

Output Set: N:\CRF3\06042002\I894550.raw

```

70 <400> SEQUENCE: 3
72 Thr Lys Gly Gly Gln Asp Ile Thr Asp Phe Gln Ile Leu Glu Asn Gln
73 1 5 10 15
76 <210> SEQ ID NO: 4
77 <211> LENGTH: 153
78 <212> TYPE: PRT
79 <213> ORGANISM: Artificial Sequence
81 <220> FEATURE:
82 <223> OTHER INFORMATION: hybrid peptide
84 <400> SEQUENCE: 4
86 Ala Pro Val Arg Ser Leu Asn Cys Thr Leu Arg Asp Ser Gln Gln Lys
87 1 5 10 15
90 Ser Leu Val Met Ser Gly Pro Tyr Glu Leu Lys Ala Leu His Leu Gln
91 20 25 30
94 Gly Gln Asp Met Glu Gln Gln Val Val Phe Ser Met Gly Ala Tyr Lys
95 35 40 45
98 Ser Ser Lys Asp Asp Ala Lys Ile Thr Val Ile Leu Gly Leu Lys Glu
99 50 55 60
102 Lys Asn Leu Tyr Leu Ser Cys Val Leu Lys Asp Asp Lys Pro Thr Leu
103 65 70 75 80
106 Gln Leu Glu Ser Val Asp Pro Lys Asn Tyr Pro Lys Lys Lys Met Glu
107 85 90 95
110 Lys Arg Phe Val Phe Asn Lys Ile Glu Ile Asn Asn Lys Leu Glu Phe
111 100 105 110
114 Glu Ser Ala Gln Phe Pro Asn Trp Tyr Ile Ser Thr Ser Gln Ala Glu
115 115 120 125
118 Asn Met Pro Val Phe Leu Gly Gly Thr Lys Gly Gly Gln Asp Ile Thr
119 130 135 140
122 Asp Phe Thr Met Gln Phe Val Ser Ser
123 145 150

```

RAW SEQUENCE LISTING ERROR SUMMARY  
PATENT APPLICATION: US/09/894,550

DATE: 06/04/2002  
TIME: 13:25:52

Input Set : A:\083AUSSEQ LST.txt  
Output Set: N:\CRF3\06042002\I894550.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:2; Xaa Pos. 18